About Almirall

Foundation of Laboratory Almirall, S.A

Almirall starts its research and development activities.

Launch of an antacid in Spain.

Launch of antihistamines in Spain and licensing on an international scale.

Creation of Laboratorios Almirall Prodesfarma S.A., as a result of the merger between the Grupo Pharmaceutics Almirall, S.A. and the Grupo Prodesfarma.

Almirall acquires Hermal, a European prescription dermatology business of Reckitt Benckiser.

The European Medicines Agency (EMA) approves the commercialisation of Almirall's treatment for chronic obstructive pulmonary disease (COPD) in Europe.

Almirall reaches an agreement to acquire Aqua Pharmaceuticals, a US-based specialist dermatology company.

Almirall transfers to AstraZeneca the rights to its respiratory franchise, including the development and commercialisation of Almirall’s existing proprietary respiratory business, rights to revenues from Almirall’s partnerships, and its pipeline of investigational novel therapies.

Acquisition of Poli Group, a pharmaceutical company which specialises in dermatology and is the world leader in nail diseases, and in treating disorders such as onychomycosis, nail psoriasis, nail dystrophy, skin mycosis, rosacea, and acne, among others.

Almirall and Sun Pharmaceutical Industries Ltd. sign a licensing agreement for the development and commercialisation of tildrakizumab in Europe, a novel biologic treatment for patients with moderate-to-severe plaque psoriasis.

European approval of a new biologic treatment for moderate‑to‑severe psoriasis, marking Almirall’s entry into the biological drugs market.

Almirall launched a novel oral antibiotic specifically developed for acne in the US, and obtained exclusive rights to develop and commercialise a new biologic treatment for atopic dermatitis and other indications in Europe.

FDA approval of an innovative topical therapy for actinic keratosis.

Agreement granting European rights to a new topical treatment for plaque psoriasis, and approval and launch of an innovative topical therapy to treat actinic keratosis in Europe.

 

European launch of a new topical formulation for plaque psoriasis, and a new licensing agreement with Simcere for IL-2muFc.

European approval and launch of a biologic treatment for moderate-to severe atopic dermatitis in Germany, and SBTi’s validation of Almirall’s emission reduction targets for 2030 and net-zero emissions goal for 2050

Obtained two exclusive license agreements for the development of two assets: a new candidate targeting immune-inflammatory dermatologic diseases, and another asset for rare dermatological conditions.

Almirall entered into a sustained, double-digit growth era and ranked among the world’s 500 most sustainable companies, as compiled by Time and Statista. Almirall also expanded key partnerships with Simcere, Absci, and the Barcelona Supercomputing Center (BSC), and strengthened its presence in China.